Get the Daily Brief
Latest Biotech News
Advancements in Parkinson’s Disease: Genomic and Clinical Insights
Recent research elucidates the influence of GBA1 genetic variant severity and polygenic background on Parkinson’s disease penetrance, reflecting personalized disease risk. Additional studies...
BioNTech Acquires CureVac to End mRNA Patent Litigation
BioNTech announced an all-stock acquisition of CureVac valued at approximately $1.25 billion, ending a protracted patent dispute over mRNA vaccine technology. CureVac shareholders will receive...
Single-Cell Atlas Collaboration Targets Cancer Plasticity
The Wellcome Sanger Institute, Helmholtz Munich, and Parse Biosciences are collaborating to create a comprehensive single-cell atlas profiling cancer plasticity and treatment response. The...
BioNTech Buys CureVac in $1.25 Billion Stock Deal to End mRNA Lawsuit
BioNTech announced the acquisition of CureVac in an all-stock transaction valued at about $1.25 billion, resolving years of patent litigation between the two German mRNA vaccine developers. The...
Enhanced CAR-T Cells Resist Death, Boost Efficacy in Solid Tumors
Scientists engineered IFN-γ-resistant CD28 CAR-T cells that show increased survival and heightened anti-tumor activity in solid tumor models. This breakthrough overcomes a key limitation in CAR-T...
FDA Delay Limits KalVista’s On-Demand HAE Drug Approval Timeline
KalVista Pharmaceuticals reported that the FDA has delayed its decision on the company's oral on-demand treatment for hereditary angioedema, citing agency workload and limited resources. This...
BioNTech Acquires CureVac to Settle mRNA Patent Dispute
BioNTech announced an all-stock acquisition of German mRNA vaccine peer CureVac for approximately $1.25 billion. The deal, positioned as a resolution to ongoing patent litigation between the...
FDA Expands RSV Vaccine Approval for Adults
Moderna’s RSV vaccine received FDA approval to expand its use to include certain younger adults aged 18 to 59 at increased risk for RSV infection. This regulatory expansion follows recent changes...
New Platform Enables Rapid Vascular Organoid Generation
Researchers developed a fast, defined method to generate vascular organoids from human iPSCs by simultaneous transcription factor activation driving endothelial and mural lineage differentiation....
FDA Approves UroGen’s Bladder Cancer Hydrogel Despite Advisory Vote
The FDA approved UroGen’s Zusduri (mitomycin formulation) for recurrent low-grade, intermediate-risk, non-muscle invasive bladder cancer after a narrowly negative advisory committee vote. Clinical...
Broad-Spectrum Coronavirus Drug Discovered via AI Modeling
An interdisciplinary team at Harvard’s Wyss Institute employed AI-enabled physics-based molecular modeling combined with molecular dynamics to repurpose and optimize FDA-approved drugs,...
New Optical Clock Network Advances Next-Gen Timekeeping
An international collaboration demonstrated the most extensive coordinated comparison of optical lattice clocks across six countries, linked by advanced frequency transfer technology. The...
CRISPR-Enhanced CAR-T Cells Show Improved Solid Tumor Activity
Massachusetts General Hospital researchers engineered IFN-γ-resistant CD28 CAR-T cells that partially evade activation-induced cell death, enhancing survival and anti-tumor efficacy in multiple...
Nanopore-Only Genome Assemblies Enabled by Novel Algorithm
Dana-Farber researchers developed Hifiasm (ONT), an algorithm capable of assembling near telomere-to-telomere human genomes using standard nanopore sequencing reads without requiring ultra-long...
Data-Driven Subtypes Reveal Parkinson’s Disease Heterogeneity
A study leveraging deep gray matter atrophy and dopamine availability imaging identified distinct clinical subtypes of early Parkinson’s disease. The subtypes correlate with specific phenotypic...
KalVista Drug Approval Delay Cited Due to FDA Resource Constraints
KalVista Pharmaceuticals disclosed FDA postponement of its regulatory decision for an oral on-demand hereditary angioedema treatment, attributing the delay to the agency’s heavy workload and...
Wojcicki’s Nonprofit Triumphs: TTAM Secures 23andMe for $305 Million
Anne Wojcicki's TTAM Research Institute outbid Regeneron Pharmaceuticals to acquire 23andMe's assets for $305 million in a second auction, securing the company's Personal Genome Service and more....
Seed Funding Boosts Elkedonia’s Neuroplastogen for Depression
Elkedonia SAS raised €11 million in a seed round to support clinical development of its first-in-class ELK-1 inhibitor for refractory depression, targeting neuroplasticity pathways. This funding...
ADC Therapeutics Cuts UK R&D and Workforce by 30%
Following the discontinuation of key clinical candidates, ADC Therapeutics is closing its UK research site and reducing its workforce by 30%. The restructuring aims to refocus resources on...
Wojcicki’s Nonprofit Triumphs: TTAM Secures 23andMe for $305 Million
Anne Wojcicki's TTAM Research Institute outbids Regeneron to acquire 23andMe assets for $305 million, reinforcing the company's founding vision. The nonprofit commits to strict privacy measures,...